Argenx also announced preliminary global net Vyvgart revenues for the fourth quarter and full-year 2022 of approximately $175M and $402M, respectively. As of December 31, 2022, argenx had approximately $2.2B in cash, cash equivalents and current financial assets*. Based on its current operating plans and a projected 2023 cash burn of approximately $500M, Argenx expects its existing cash, cash equivalents and current financial assets, together with anticipated future product revenues, to fund the company to profitability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- Argenx price target raised to EUR 500 from EUR 480 at JPMorgan
- Argenx included on Wells Fargo’s Tactical Ideas List for Q1 2023
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference